| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
α-Acetobromoglucose is used as a glycosyl donor in glycosylation reactions. Its mechanism of action involves the addition of a glycosyl group to another molecule, typically a protein or lipid, through a process known as glycosylation. The compound is essential for constructing tailored glycan structures and probing carbohydrate-mediated biological processes. It is used as a possible PET surface modification reagent to increase blood compatibility.
|
|---|---|
| ln Vitro |
In vitro, α-acetobromoglucose is used as a glycosyl donor for glycosylation reactions. It is particularly useful in the synthesis of various active compounds, enhancing the efficiency of carbohydrate chemistry. The compound is widely utilized in glycobiology and medicinal chemistry research for constructing tailored glycan structures and probing carbohydrate-mediated biological processes. It is an indispensable player in antiviral drug development.
|
| ln Vivo |
In vivo data for α-acetobromoglucose as a therapeutic agent are limited. The compound is a glycosyl donor used primarily for in vitro synthesis and research applications. Its use as a PET surface modification reagent to increase blood compatibility suggests potential for biomedical applications. However, specific in vivo pharmacokinetic and pharmacodynamic data are not well-documented.
|
| Enzyme Assay |
For in vitro chemical synthesis, α-acetobromoglucose is used as a glycosyl donor in glycosylation reactions. Standard protocols involve reacting the compound with an acceptor (e.g., alcohol, amine) in the presence of a promoter (e.g., silver triflate, mercury salts) in an appropriate solvent. The glycosylation reaction forms glycosidic bonds, enabling the assembly of complex oligosaccharides and glycoconjugates.
|
| Cell Assay |
For in vitro cell-based experiments, α-acetobromoglucose is not typically used directly in cell culture as a test compound. It is a chemical reagent used for glycosylation synthesis and glycobiology research. The compound may be used in the synthesis of glycosylated compounds that are subsequently tested in cell-based assays, but it is not added directly to cell cultures as a test compound.
|
| Animal Protocol |
In vivo animal studies for α-acetobromoglucose are limited. The compound may be used in studies evaluating the biocompatibility of glycosylated materials or in antiviral drug development. Standard in vivo protocols involve administration to rodents via appropriate routes with measurement of relevant biological endpoints. Specific protocols for this compound are not well-documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of α-acetobromoglucose are not characterized as a drug. The compound has a molecular weight of 411.20 g/mol. As a glycosyl donor, it is chemically reactive and would be expected to be rapidly hydrolyzed or metabolized in biological systems. The compound is primarily used as a reagent rather than as a drug candidate.
|
| Toxicity/Toxicokinetics |
α-Acetobromoglucose is a research chemical and should be handled with appropriate laboratory safety precautions. As a brominated compound, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
α-Acetobromoglucose (2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide, CAS 572-09-8) is primarily a research-grade chemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a glycosyl donor for glycosylation reactions in glycobiology and medicinal chemistry research. The compound is used in antiviral drug development and as a PET surface modification reagent. No clinical trials or approved therapeutic indications exist.
|
| Molecular Formula |
C14H19BRO9
|
|---|---|
| Molecular Weight |
411.20
|
| Exact Mass |
410.021
|
| CAS # |
572-09-8
|
| PubChem CID |
101776
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
412.0±45.0 °C at 760 mmHg
|
| Melting Point |
83-88ºC
|
| Flash Point |
203.0±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.503
|
| LogP |
2.05
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
24
|
| Complexity |
507
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)Br)OC(=O)C)OC(=O)C)OC(=O)C
|
| InChi Key |
CYAYKKUWALRRPA-RGDJUOJXSA-N
|
| InChi Code |
InChI=1S/C14H19BrO9/c1-6(16)20-5-10-11(21-7(2)17)12(22-8(3)18)13(14(15)24-10)23-9(4)19/h10-14H,5H2,1-4H3/t10-,11-,12+,13-,14+/m1/s1
|
| Chemical Name |
[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-bromooxan-2-yl]methyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4319 mL | 12.1595 mL | 24.3191 mL | |
| 5 mM | 0.4864 mL | 2.4319 mL | 4.8638 mL | |
| 10 mM | 0.2432 mL | 1.2160 mL | 2.4319 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
